Prosomnus, Inc.



This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 2, 2023 (the "Prospectus") filed by ProSomnus, Inc. (the "Company") with the information contained in the Company's Current Report on Form 8-K, filed with the SEC on August 18, 2023. Accordingly, we have attached such Current Report on Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common stock and our public warrants are listed on the Nasdaq Global Market and Nasdaq Capital Market, respectively, under the symbols "OSA" and "OSAAW," respectively. On August 17, 2023, the closing price of our common stock was \$1.03 and the closing price for our public warrants was \$0.03.

We are an "emerging growth company" as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements.

Investing in our securities is highly speculative and involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in "Risk Factors" beginning on page 13 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 18, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2023

PROSOMNUS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41567	88-2978216
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
5675 Gibralt	ar Avenue	
Pleasanton, CA		94588
(Address of Principal	Executive Offices)	(Zip Code)
Registrant's	telephone number, including area code: (844) 5	37-5337
(Former	name or former address, if changed since last re	eport)
Check the appropriate box below if the Form 8-K fill following provisions:	ing is intended to simultaneously satisfy the	filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under	er the Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 under t	he Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pursuant to R	tule 14d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))
☐ Pre-commencement communications pursuant to R	tule 13e-4(c) under the Exchange Act (17 CFR	240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Ac	t:	
		Name of each exchange
	Trading	on
Title of each class	Symbol(s)	which registered
Common Stock, par value \$0.0001 per share	OSA	The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one		
share of Common Stock for \$11.50 per share	OSAAW	The Nasdaq Stock Market LLC
· · · · · · · · · · · · · · · · · · ·	nerging growth company as defined in Rule 4	•
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an en	nerging growth company as defined in Rule 4	•
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act o Emerging growth company ⊠	nerging growth company as defined in Rule 4 f 1934 (§240.12b-2 of this chapter).	05 of the Securities Act of 1933 (§230.405 of this
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act o	nerging growth company as defined in Rule 4 f 1934 (§240.12b-2 of this chapter). k if the registrant has elected not to use the ext	05 of the Securities Act of 1933 (§230.405 of this
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act of Emerging growth company If an emerging growth company, indicate by check mark	nerging growth company as defined in Rule 4 f 1934 (§240.12b-2 of this chapter). k if the registrant has elected not to use the ext	05 of the Securities Act of 1933 (§230.405 of this
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act of Emerging growth company If an emerging growth company, indicate by check mark	nerging growth company as defined in Rule 4 f 1934 (§240.12b-2 of this chapter). k if the registrant has elected not to use the ext	05 of the Securities Act of 1933 (§230.405 of this
share of Common Stock for \$11.50 per share Indicate by check mark whether the registrant is an enchapter) or Rule 12b-2 of the Securities Exchange Act of Emerging growth company If an emerging growth company, indicate by check mark	nerging growth company as defined in Rule 4 f 1934 (§240.12b-2 of this chapter). k if the registrant has elected not to use the ext	05 of the Securities Act of 1933 (§230.405 of this

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 14, 2023, ProSomnus, Inc. (the "Company") received written notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities ("MVLS") of \$50,000,000 required for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Requirement"). The Notice has no effect at this time on the listing of the Company's common stock (the "Common Stock"), which continues to trade on the Nasdaq Global Market under the symbol "OSA".

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a period of 180 calendar days, or until February 12, 2024 (the "Compliance Date"), to regain compliance with the MVLS Requirement. To regain compliance, the Company's MVLS must close at \$50,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date. The Company intends to actively monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the MVLS Requirement. The Company may also choose to transfer the listing of its Common Stock to the Nasdaq Capital Market. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A), or maintain compliance with any other listing requirements, or satisfy the requirements necessary to transfer the listing of its Common Stock to the Nasdaq Capital Market.

Forward-looking statements

This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not purely historical regarding the Company's or its management's intentions, beliefs, expectations and strategies for the future, including statements regarding the Company's ability to regain compliance with the MVLS Requirement, the Company's intentions to actively monitor its MVLS, the Company's plans to consider implementing available options to regain compliance with the MVLS Requirement, and the Company's intent to consider transferring the listing of its Common Stock to the Nasdaq Capital Market. All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company, deal with future events, are subject to various risks and uncertainties, including the risk that the Company may not meet the MVLS Requirement by the Compliance Date or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from the Company's current expectations are more fully described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 14, 2023, any subsequently filed Quarterly Reports on F

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROSOMNUS, INC.

By: /s/ Brian B. Dow

Name: Brian B. Dow Title: Chief Financial Officer

Dated: August 18, 2023